Eli Lilly's weight-loss drug misses Wall Street expectations, shares tumble
Lilly's shares fall nearly 12% as drug sales miss expectations
CEO David Ricks cited excess supply and delayed advertising for the shortfall
Lilly slashes annual profit forecast due to acquisition charges and higher costs
Adds graphic, data on Zepbound prescriptions in paragraph 7, and investor comment in paragraph 16; updates shares, paragraph 2
By Bhanvi Satija and Patrick Wingrove
Oct 30 (Reuters) -Eli Lilly's LLY.N high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the company after long struggling to meet outsized demand.
Lilly shares fell nearly 12%, wiping out more than $100 billion from the Indianapolis-based drugmaker's market value.
Both its weight-loss drug Zepbound and diabetes treatment Mounjaro have been contending with high demand that has led to shortages, but last quarter Lilly said it had ramped up manufacturing and was able to fill back orders at wholesalers. Now Lilly's drugs are no longer in shortage and distributors are working through the supplies, it said.
Drug wholesalers, or distributors, purchase medicines like Zepbound from manufacturers and sell them to hospitals, clinics, pharmacies and other healthcare providers.
Lilly CEO David Ricks told CNBC there was excess supply of the drugs but that the company had not yet started advertising Zepbound and had held back on international launches to focus on increasing U.S. inventory.
"We haven't been stimulating demand the way we had originally planned," Ricks said.
Sales of Mounjaro were $3.11 billion, while Zepbound brought in $1.26 billion, which Lilly said reflected continued strong demand.
Analysts were looking for sales of $4.20 billion for Mounjaro and $1.69 billion for Zepbound for the quarter, according to LSEG data. They expect the drugs to make a combined $19 billion this year.
The miss comes despite prescriptions of Zepbound and Mounjaro continuing to increase in the U.S. Lilly filled an average of around 140,000 Zepbound prescriptions per week this quarter, compared to just over 93,000 per week last quarter, according to IQVIA data shared by an analyst.
J.P. Morgan analyst Chris Schott said the results suggested wholesalers had utilized their existing inventories without placing additional new orders as analysts had expected.
Lilly's shares had been up 55% so far this year, making it the world's most valuable healthcare company, as investors bet on the success of the weight-loss drug.
Mounjaro and Zepbound compete with Novo Nordisk's NOVOb.CO popular Ozempic and Wegovy. Novo, whose U.S. listed shares were down almost 1%, has been aggressively marketing Wegovy on U.S. television.
Lilly also slashed its annual adjusted profit forecast to $13.02 to $13.52 per share, compared to prior view of $16.10 to $16.60, citing acquisition charges in the third quarter.
The previously disclosed $2.8 billion acquisition-related charge and higher manufacturing costs also contributed to the third-quarter profit miss.
'A BLIP IN THE ROAD'
Zepbound and Mounjaro were in short supply for much of this year due to soaring demand for the medicines that have been shown to help patients lose an average of 20% of their weight. Lilly said supply had started to catch up with demand last quarter.
David Heupel, senior portfolio manager at Thrivent Financial for Lutherans, which owns about 370,000 Lilly shares, called third-quarter results "a blip in the road" and said he was not concerned about overall demand for Lilly's weight-loss and diabetes drugs.
It's just "a consequence of a market that's still in its infancy," Heupel said.
Lilly has invested billions of dollars to expand production of Mounjaro and Zepbound, both known chemically as tirzepatide, including about $7 billion in its Indiana site and facilities in Ireland. The drug is sold under the brand name Mounjaro for both diabetes and weight loss outside the U.S.
Lilly trimmed the upper end of its full-year sales forecast by $600 million to $46 billion. It maintained the lower end at $45.4 billion.
Lilly and Novo Nordisk have been racing to increase capacity and meet unprecedented demand for a weight-loss market some analysts estimate could reach $150 billion in annual revenue by the next decade.
In August, Novo trimmed its full-year profit forecast and reported a rare miss on quarterly sales of Wegovy.
Zepbound and Mounjaro prescriptions https://reut.rs/3YILy49
Reporting by Bhanvi Satija and Christy Santhosh in Bengaluru and Patrick Wingrove in New York; Editing by Sriraj Kalluvila and Bill Berkrot
آخر الأخبار
إخلاء المسؤولية: تتيح كيانات XM Group خدمة تنفيذية فقط والدخول إلى منصة تداولنا عبر الإنترنت، مما يسمح للشخص بمشاهدة و/أو استخدام المحتوى المتاح على موقع الويب أو عن طريقه، وهذا المحتوى لا يراد به التغيير أو التوسع عن ذلك. يخضع هذا الدخول والاستخدام دائماً لما يلي: (1) الشروط والأحكام؛ (2) تحذيرات المخاطر؛ (3) إخلاء المسؤولية الكامل. لذلك يُقدم هذا المحتوى على أنه ليس أكثر من معلومات عامة. تحديداً، يرجى الانتباه إلى أن المحتوى المتاح على منصة تداولنا عبر الإنترنت ليس طلباً أو عرضاً لدخول أي معاملات في الأسواق المالية. التداول في أي سوق مالي به مخاطرة عالية برأس مالك.
جميع المواد المنشورة على منصة تداولنا مخصصة للأغراض التعليمية/المعلوماتية فقط ولا تحتوي - ولا ينبغي اعتبار أنها تحتوي - على نصائح أو توصيات مالية أو ضريبية أو تجارية، أو سجلاً لأسعار تداولنا، أو عرضاً أو طلباً لأي معاملة في أي صكوك مالية أو عروض ترويجية مالية لا داعي لها.
أي محتوى تابع للغير بالإضافة إلى المحتوى الذي أعدته XM، مثل الآراء، والأخبار، والأبحاث، والتحليلات والأسعار وغيرها من المعلومات أو روابط مواقع تابعة للغير وواردة في هذا الموقع تُقدم لك "كما هي"، كتعليق عام على السوق ولا تعتبر نصيحة استثمارية. يجب ألا يُفسر أي محتوى على أنه بحث استثماري، وأن تلاحظ وتقبل أن المحتوى غير مُعدٍ وفقاً للمتطلبات القانونية المصممة لتعزيز استقلالية البحث الاستثماري، وبالتالي، فهو بمثابة تواصل تسويقي بموجب القوانين واللوائح ذات الصلة. فضلاً تأكد من أنك قد قرأت وفهمت الإخطار بالبحوث الاستثمارية غير المستقلة والتحذير من مخاطر المعلومات السابقة، والذي يمكنك الاطلاع عليه هنا.
